Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 1972-1973, 2004; 10.1373/clinchem.2004.040774
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delanghe, J. R.
Right arrow Articles by De Buyzere, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delanghe, J. R.
Right arrow Articles by De Buyzere, M. L.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2004;50:1972-1973.)
© 2004 American Association for Clinical Chemistry, Inc.

Editorials

Development of an ELISA for the Determination of the Major Haptoglobin Phenotype: An Interesting Technical Development and Its Potential Consequences

Joris R. Delanghea and Marc L. De Buyzere

1 Department of Clinical Chemistry, University Hospital Ghent (2P8), De Pintelaan 185, B9000 Ghent, Belgium

aAuthor for correspondence. E-mail Joris.delanghe@ugent.be.

The first 20% of the full text of this article appears below.

In this issue, Levy and Levy (1) report on the development of an ELISA using single-chain antibodies (ScAbs) from a phage library for the determination of the major haptoglobin (Hp) phenotype in serum. This technical achievement is remarkable as the structural differences between the major Hp phenotypes 1-1, 2-1, and 2-2 are only minor (2). Apart from a single junction at the site of duplication of exon 3, there are no differences in primary amino acid sequence between the Hp alleles Hp1 and Hp2. The authors have taken advantage of the unique polymeric differences among Hp phenotypes to develop their ScAb-based ELISA.

ScAbs have been used for several years as a tool in the biomedical research laboratory. They have been applied in areas such as antibody and protein engineering, enzyme technology, vaccine development, and ligand-receptor studies with applications in oncology and immunology (3). The . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.